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The ε4 allele of APOE confers a two- to fourfold increased risk for late-onset Alzheimer’s disease (LOAD), but LOAD pathology does not all
fit neatly around APOE. It is conceivable that genetic variation proximate to APOE contributes to LOAD risk. Therefore, we investigated the
degree of linkage disequilibrium (LD) for a comprehensive set of 50 SNPs in and surrounding APOE using a substantial Caucasian sample of
1100 chromosomes. SNPs in APOE were further molecularly haplotyped to determine their phases. One set of SNPs in TOMM40, roughly 15 kb
upstream of APOE, showed intriguing LD with the ε4 allele and was strongly associated with the risk for developing LOAD. However, when all
the SNPs were entered into a logit model, only the effect of APOE ε4 remained significant. These observations diminish the possibility that loci in
the TOMM40 gene may have a major effect on the risk for LOAD in Caucasians.
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confers risk for both coronary artery disease (CAD) [1] and
Alzheimer’s disease (AD) [2]. The connection of this gene to
CAD is apparent because the ApoE protein, as a component of
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doi:10.1016/j.ygeno.2007.02.002mediates lipoprotein uptake, and thus has direct effects on lipid
metabolism. In addition, both functional and regulatory varia-
tions in APOE account for population-level variation in meta-
bolic lipid levels [3]. The connection between ApoE and AD
pathogenesis is more obscure. The major APOE risk for AD is
generally assumed to come from the ε2/ε3/ε4 haplotype system,
with the ε4 allele increasing risk for both disorders and the ε2
allele being protective [4]. However, recent estimates of heri-
tability of AD range from 57% to 78% [5], with ε4 alleles
accounting for only roughly 50% of that heritability.
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ymous single-nucleotide polymorphisms (SNPs) in APOE exon
4. One is a C/T SNP (rs429358) that encodes either arginine (C)
or cysteine (T) in ApoE at amino acid 112. The second site
defining this haplotype system is a C/T SNP (rs7412), which
again encodes arginine (C) or cysteine (T) at ApoE amino acid
158. The allelic compositions of the commonly investigated
haplotypes are TT for ε2, TC for ε3, and CC for ε4. The effects
of these coding variants on ApoE function are well defined [6].
Regulation of APOE expression is controlled by cis-acting
elements both within the gene and in flanking sequences. The
function of these regulatory elements could potentially be
influenced by genetic variation. Variation in the 5′ promoter
region of APOE alters its expression [7,8], and some of these
variants may be associated with AD [9], although their impact
appears to be minor. In fact, it has proven difficult to provide
good estimates of the effect of the 5′ regulatory variation on risk
for AD, in part because these SNPs could be in linkage
disequilibrium (LD) with ε4. There are numerous noncoding
SNPs within and immediately adjacent to APOE that may
influence measures of lipid metabolism [10].
Variation just outside of the 3′untranslated region of APOE
has also been reported to have a minor impact on risk for late-
onset Alzheimer's disease (LOAD) [11]. Again, LD potentially
confounds interpretation of the association. Downstream
regulatory elements include two copies of a multienhancer
that control expression of APOE in adipocytes, macrophages,
and astrocytes (ME1 and ME2) [12,13], two copies of a hepatic
control region (HCR1 and HCR2) [14,15] enhancer that control
expression in the liver; and a potential brain control region
42 kb from APOE that may control expression in brain neurons
and microglia [16]. It is unknown whether genetic variation in
or near these elements controls APOE expression. What of the
genes and genetic variants outside but potentially in LD with ε4
of APOE? For example, based on results from cladistic
analyses, Templeton [17] argued that variation in APOC1
causes risk for LOAD. Also unknown is whether there are
additional cis-elements upstream of the APOE promoter that
contribute to this risk.
Because of the strong association between the ε2/ε3/ε4
variants of APOE and the risk for AD, we investigated the LD
structure of APOE and its surrounding region. Of particular
interest are SNPs in potential regulatory regions both within and
flanking APOE that could modify the risk associated with the
ε2/ε3/ε4 haplotypes. Also, APOE is an excellent model to
explore the ability of genome-wide association methods to
detect a causative gene when risk for a common disease is
determined by a single, monophyletic, common variant therein.
To characterize the APOE-region LD structure, we genotyped
50 SNPs in and surrounding APOE, with particular reference to
the ε2, ε3, and ε4 system of alleles. The 550 Caucasian samples
genotyped were collected to evaluate the genetic basis of AD.
Within APOE itself, we report on 21 SNPs that were
molecularly phased using the methods reported in Yu et al.
[18]. This set of SNPs overlaps substantially with those assayed
by Fullerton et al. [19]. Outside of APOE, we relied on
statistical methods to infer haplotypes or assess LD. In our studypopulation, we assessed whether selection on ε4 (or possibly
other loci in the region) alters the pattern of LD found in the AD
sample relative to that found in the control sample. Significant
LD was observed between ε4 and SNPs spanning 50 kb, a
region containing multiple genes. Because of the LD patterns
observed, it is difficult to distinguish the impact of ε4 from
highly correlated SNPs in the region. In terms of detecting
APOE as an AD risk gene, there are numerous SNPs in the
region that would detect AD risk, but interestingly, they are not
necessarily in APOE. In fact, some of the SNPs with the greatest
power to detect risk are in the adjacent gene TOMM40, while
many others much closer to ε4 would not be useful.
Results
Genotype data of 50 loci (Fig. 1, Supplementary Table 1) in
the APOE region were generated from a clinical sample of 550
Caucasians. Among the subjects, 193 individuals had a clinical
diagnosis of LOAD, 125 individuals had diagnoses of other
neurodegenerative disorders, and 232 individuals were controls.
For our combined samples, 16 of the 21 APOE loci were
polymorphic, and 11 of 21 had a minor allele frequency (MAF)
>0.05 (Supplementary Table 1). The remaining 29 loci, those
outside of APOE, were selected to have MAF >0.02 in the
samples. After Bonferroni correction for multiple testing, two
loci violated Hardy–Weinberg (HW) assumptions in the LOAD
sample (SNP 8 [rs6857] and SNP 11 [rs11556505]), a third
locus violated HW in the control sample (SNP 1 [rs2965118]),
and all three of these loci violated HW when the data were
combined to produce the full sample (data not shown). None of
the loci within APOE violated HW in any of the samples. SNPs
in APOE were further haplotyped by molecular methods to
determine their phases. We used the Allele Discriminating Long
and Accurate PCR Haplotyping (ADLAPH) method [18] to
produce unambiguous molecular haplotypes for 21 loci in
APOE (SNPs 17–37, Fig. 1, Supplementary Table 1) from our
study samples.
LD pattern within APOE
Genotyping error
Of the 550 individuals genotyped and 1100 haplotypes deter-
mined for the 21 APOE loci, 12 were singleton haplotypes. We
reasoned that some of these singleton haplotypes could result
from genotyping error because an error would have a
nonnegligible probability of producing a novel, albeit pseudo-
haplotype. To address the question of the rate of genotyping
error, we performed two analyses, one computational and the
other molecular (for details, see Materials and methods). We
estimate a per-locus error rate of 0.0003 with an upper 95%
confidence interval of 0.0006.
Corrected haplotype distribution
If the APOE loci were in linkage equilibrium, then we would
expect hundreds of different haplotypes. Because these SNPs
fall within a 5300-bp region, we do not expect such a substantial
set of haplotypes. Only 35 unique haplotypes are observed in
Fig. 1. SNP map of APOE and its surrounding region. A 215-kb genomic section containing nine genes, five APOE regulatory elements, and 50 SNPs analyzed in this
study is shown. APOE and its flanking region are further enlarged. Detailed information of the 50 SNPs is given in Supplementary Table 1.
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a few common haplotypes (Table 1). Five haplotypes account
for over 75% of the haplotype distribution, and 13 haplotypes
account for over 95% of the haplotype distribution. The com-
mon haplotypes are common in both the LOAD and the control
samples, although individual haplotypes clearly differ in
frequency (Table 1), especially with respect to the presence/
absence of ε4. After accounting for errors, nine singleton
haplotypes occur in the 1100 haplotypes. These singletons are
evenly distributed across the samples: for the LOAD sample,
the relative frequency of singletons is 0.008; for the control
sample, it is 0.006; and for the miscellaneous sample it is 0.008.
In the total sample, 61 chromosomes carry ε2 on three
different haplotypes (Table 1), 741 chromosomes carry ε3 on
20 different haplotypes, and 298 chromosomes carry ε4 on 12
different haplotypes. Contrasting the case and control samples
(Table 1), the case sample contains 11, 210, and 165 haplo-
types bearing ε2/ε3/ε4 alleles (n=386), respectively, whereas
the control sample contains 39, 353, and 72 haplotypes bearing
ε2/ε3/ε4 alleles (n=464).
LD
To analyze the “haplotype-block” structure of APOE, as
measured by the diversity of the haplotype distribution [20], we
restricted the data to the 11 SNPs with MAF >0.02 (see Sup-
plementary Table 1). Results from this analysis are congruent
with the restricted distribution of haplotypes in Table 1,
suggesting that all but the last locus of APOE form a single
haplotype block. Analyses for a recombination hot spot were
more ambiguous: some runs of Phase 2 found no evidence for a
recombination hot spot within these loci (mean posterior
likelihood of 1.0 across the region), whereas other runs placed
a hot spot in the vicinity of loci 21–23 (rs449647 and rs769446,mean posterior likelihood of 276.7). The pattern of pair-wise
LD in the gene (as measured by a common metric, D′ [21]) is
compatible with the haplotype structure of the gene (Supple-
mentary Fig. 1), suggesting complete LD for most pairs of loci.
The complementary results of limited haplotype diversity,
substantialD′, and limited evidence for recombination hot spots
suggest that recombination has not been a major evolutionary
factor within APOE. By contrast, another common measure of
pair-wise LD, namely r2 or Δ2 [21], is not uniformly large;
instead, pair-wise LD varies substantially and is often small (Fig.
2). This measure is also a function of recombination, but is
sensitive to a host of other factors, including homoplasy [21,22].
Homoplasy in APOE has been demonstrated by Templeton
et al., who described the occurrence of a particular mutation
on more than one haplotype background in the APOE region
[22,23].
LD pattern in loci in and surrounding APOE
Pair-wise LD
In this subsection we focus largely on the ε2/ε3/ε4 system of
alleles, because of their presumed central role in the risk for
LOAD. We also use the data from individuals diagnosed with
LOAD and contrast those data with those of the controls. Fig. 2
shows the pair-wise LD between the ε2/ε3/ε4 system and other
loci. Because of the relative rarity of ε2, we centered the LD
analysis on SNP 33, which defines the ε4 versus ε3 dichotomy.
When measured by r2, LD between alleles at SNP 33 and alleles
outside of APOE shows notable variation (Fig. 2), much like the
loci in APOE. Only one SNP in APOE shows a substantial r2
with SNP 33, SNP 28, whereas a much larger number of SNPs
5′ of APOE show substantial r2 (Fig. 2). LD tends to be
unpredictable near the ε3/ε4 locus, but seems essentially absent
Table 1
Haplotypes and frequencies for all individuals (All), only individuals diagnosed with LOAD (LOAD), and only individuals who served as controls for LOAD patients
(Controls)
No. Complete haplotype All LOAD Controls
Count Freq. Count Freq. Count Freq.
1 CCACACTGGGCGATTCTCCAT ε3 241 0.2191 70 0.1814 116 0.2500
2 CCACACTTCGCGGTTCTCCAT ε3 213 0.1936 53 0.1373 107 0.2306
3 CCACACTTGGCAGTTCCCCAT ε4 204 0.1855 111 0.2876 52 0.1121
4 CCACTCTTCGCGGTTCTCCAT ε3 92 0.0836 23 0.0596 43 0.0927
5 CCACACTGGGCGATTCTCCAC ε3 91 0.0827 26 0.0674 37 0.0797
6 CCACACTGGGCGGTTCCCCCT ε4 59 0.0536 34 0.0881 14 0.0302
7 CCACTCTGGGCGGTTCTCTAT ε2 40 0.0364 8 0.0207 25 0.0539
8 CCACACCTCGTGGTTCTCCAT ε3 33 0.0300 13 0.0337 14 0.0302
9 CCACTCTGGGCGATTCTCCAT ε3 26 0.0236 9 0.0233 15 0.0323
10 CCACACCGGGCGGTTCTCTAT ε2 18 0.0164 3 0.0078 11 0.0237
11 CCACACCTGGCAGTTCCCCAT ε4 17 0.0155 9 0.0233 2 0.0043
12 CCACACCGGGCGATTCTCCAT ε3 10 0.0091 4 0.0104 5 0.0108
13 CCACACCTCGCGGTTCTCCAT ε3 9 0.0082 3 0.0078 5 0.0108
14 CCACACTGGGCGGTTCCCCAT ε4 5 0.0046 4 0.0104 0 0
15 CCACACTTCGCGGGTCTCCAT ε3 4 0.0036 1 0.0026 3 0.0065
16 CCACACTGCGCGGTTCTCCAT ε3 4 0.0036 1 0.0026 2 0.0043
17 CCACACCGGGCGATTCTCCAC ε3 3 0.0027 1 0.0026 2 0.0043
18 CCACACTTGGCAGTCCCCCAT ε4 3 0.0027 1 0.0026 2 0.0043
19 CCACACTGGGCGGTTCTCTAT ε2 3 0.0027 0 0 3 0.0065
20 CCACACTTGGCAATTCTCCAT ε3 3 0.0027 1 0.0026 0 0
21 CCACTCTGGGCGGTTCTCCAT ε3 3 0.0027 2 0.0052 0 0
22 CCACTCCTCGCGGTTCTCCAT ε3 2 0.0018 0 0 2 0.0043
23 CCGCTCTTGGCGGTTCCCCAT ε4 2 0.0018 1 0.0026 1 0.0022
24 CCACACTTGGCGGTTCTCCAT ε3 2 0.0018 2 0.0052 0 0
25 CCGCTCTGGGCGGTTCCCCAT ε4 2 0.0018 1 0.0026 0 0
26 CCACACCGGGCGGTTCCCCAT ε4 2 0.0018 2 0.0052 0 0
27 CCACACTGGGCGGTTCTCCAT ε3 1 0.0009 0 0 1 0.0022
28 CCACTCCGGGCGGTTCTCCAT ε3 1 0.0009 0 0 1 0.0022
29 CCGCACTTGGCGGTTCCCCAT ε4 1 0.0009 0 0 1 0.0022
30 TCACACTGGGCGGTTCTTCAT ε3 1 0.0009 1 0.0026 0 0
31 CCACACTTCGCAGTTCCCCAT ε4 1 0.0009 1 0.0026 0 0
32 CCACACTGGGCGGTTCCCCAC ε4 1 0.0009 1 0.0026 0 0
33 CCACTCTTGGCGGTTCCCCAT ε4 1 0.0009 0 0 0 0
34 CCACTCCTCGTGGTTCTCCAT ε3 1 0.0009 0 0 0 0
35 CCACACTTCGTGGTTCTCCAT ε3 1 0.0009 0 0 0 0
“All” contains other samples in addition to LOAD and Controls. Embedded in the 21-locus (Fig. 1 and Supplementary Table 1, SNP 17-37) haplotypes, in bold, are the
2-locus haplotypes that encode the ε2/ε3/ε4 system of alleles.
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The pattern is similar for both the LOAD and the control
samples. When LD is measured by |D′| (Fig. 2), however, the
values for most loci around SNP 33 are large (close or equal to
1) and are predictably small only at substantial distances from
SNP 33 (Supplementary Table 1, Fig. 2). Again the pattern is
similar for both the LOAD and the control samples. We do not
report hot-spot analysis for the larger region because we could
not discern a consistent pattern in the results; it appears that
numerous regions show some evidence for elevated recombina-
tion rates.
Tag SNPs
To summarize multivariate LD across these loci, as well as to
identify tag SNPs, we used the hierarchical cluster methods
proposed by Rinaldo et al. [20]. Tag SNPs were selected using a
bound of 0.8. Cluster analysis identifies only a few substantial
clusters and shows similar clustering features for both the
LOAD and the control samples (Supplementary Fig. 2). SNPsspanning roughly 50 kb and covering APOC4, APOC2, and
CLPTM1 show substantial joint LD (SNPs 41–50 in Supple-
mentary Fig. 2). This cluster, however, has no noteworthy
correlation with SNPs 33 and 35, which define the ε2/ε3/ε4
system. In terms of clustering by LD, SNPs 33 and 35 do not fall
in the same cluster regardless of whether the LOAD or control
samples were evaluated. Not only are SNPs 33 and 35 largely
independent, they do not cluster strongly with other SNPs in
APOE, with the exception of SNP 28, which clusters with
SNP 33. Interestingly, SNP 33 clusters tightly with SNPs in
TOMM40, especially SNPs 10–12 (Fig. 1), which are separated
from SNP 33 by roughly 16 kb. SNPs 10 and 11 occur in
TOMM40 exons 3 and 4, respectively. SNP 35, defining the ε2
versus ε3 dichotomy, shows modest clustering with SNP 5,
roughly 38 kb away, in the second intron of PVRL2.
HapMap SNPs
To contrast our results with data from HapMap, we down-
loaded the data from Release 21a (Phase II Jan07 on NCBI B35
Table 2
AD status versus count of ε4 alleles
Sample Count of ε4 alleles
0 1 2
All with AD 58 (30.9) 105 (54.4) 30 (15.5)
All controls 162 (61.8) 68 (29.3) 2 (0.9)
Women with AD 32 (30.9) 55 (54.4) 15 (15.5)
Women controls 91 (61.8) 45 (29.3) 2 (0.9)
Men with AD 26 (30.9) 50 (54.4) 15 (15.5)
Men controls 71 (61.8) 23 (29.3) 0 (0.9)
Fig. 2. Pair-wise LD between SNP 33 alleles (defining ε3/ε4 dichotomy) and all other loci across the region (except SNP 35, which defines the ε2/ε3 dichotomy). Left
and right show different disequilibrium measures (r2 versus |D′|) and top and bottom contrast the LOAD sample versus the sample of control individuals.
659C.-E. Yu et al. / Genomics 89 (2007) 655–665assembly, dbSNP b125; see HapMap at www.hapmap.org). This
version contains 219 SNPs spanning the same region that we
evaluated. Notably, neither SNP 33 (rs429358) defining the ε3/ε4
dichotomy nor SNP 35 (rs7412) defining the ε2/ε3 dichotomy
has genotypes in the CEU population of this version of HapMap.
Nonetheless, genotypes for two other SNPs that we have
previously shown to be highly correlated with SNP 33 (r2>0.5)
are contained therein, namely SNPs 8 (rs6857) and 16 (rs10119),
as well as other SNPs that are more moderately correlated.
Because genotypes of SNPs 8, 16, and 33 are available in both
Yoruba (YRI) and Japan (JPT) samples in HapMap, we
evaluated these SNPs’ correlation in the two ethnic groups.
Results indicated that both SNPs 8 and 16 do not correlate well
with SNP 33 (r2 =0.0 and 0.029, respectively, for SNPs 8 and 16
in YRI and r2 =0.08 and 0.101 in JPT). Therefore, LD patterns
in this region do not appear to be consistent across the different
ethnic groups; although, since SNP 8 was one of the SNPs that
deviated from Hardy–Weinberg equilibrium, we cannot exclude
the possibility that there are as yet unrecognized genotyping
artifacts, which could affect this conclusion.
Notably, the HapMap CEU data recapitulate the pattern of
LD and clustering in Caucasians shown in Supplementary Fig.
2. Strong clustering emerges over a 50-kb region that contains
the genes APOC1, APOC2, APOC4, and CLPTM1, while the
roughly 60-kb proximal region shows no substantial clustering
(data not shown). Clustering the HapMap CEU SNPs using H-
clust reveals another SNP that should be highly correlated withSNP 33, specifically rs2075650, which has an r2 of roughly
0.85 with SNP 8. Tag SNP selection using H-clust and the
HapMap data always draws an SNP highly correlated with SNP
33, for a wide range of stringency of SNP selection, even to
r2 =0.20 (data not shown). Therefore a genome-wide or local
association scan built from HapMap data would very likely
detect association with LOAD for regional SNPs, assuming the
scan were adequately powered.
Disease marker association
APOE and ε4 count
As has been demonstrated for many different samples, the
distribution of ε4 alleles (Table 2) differs substantially between
AD and control samples (χ2 =78.6605, df=2, p≤2.2×10−16).
When evaluated by sex, the distribution of ε4 alleles did not
Fig. 4. Results of association analyses for AD status versus individual SNP
genotypes, with or without taking count of ε4.
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df=2, p=0.89) or between men and women in the control
samples (χ2 =2.01, df=1, p=0.16). Analysis of age at AD
diagnosis, performed using a Cox proportional hazards model,
shows time to diagnosis is strongly dependent on ε4 count (β=
−1.07, SE=0.111, z=9.67, p∼0.0). Survival analysis models
with gender and ε4/gender interaction reveal no additional
significant covariates.
Other SNPs in APOE
Within APOE, 11 SNPs were sufficiently polymorphic for
inference using measured haplotype analysis (MHA) [24].
MHA uses inferred evolutionary relationships among haplo-
types, specified in the form of a cladogram, to structure the tests
of association. The network relating all haplotypes with one-
step mutations is given in Fig. 3a; only one haplotype is not
connected in this network, and it differs from three other
haplotypes by two mutational steps. Evolutionary rules [23]
break the cycles in the network to produce a cladogram (Fig. 3b)
of haplotypes connected by one-step mutations. The cladogram
has the plausible feature of clustering ε4- and ε3-containing
haplotypes, but the three ε2-containing haplotypes are implau-
sibly separated in the evolutionary space. The latter is of little
concern given the modest impact of ε2, and in fact, the results do
not differ if the haplotypes are grouped (results not shown). We
simplify the cladogram for statistical inference by consolidating
rare haplotypes with more common haplotypes, because the
impact on risk of rare haplotypes—even if it were substantially
different from adjoining haplotypes—could not be distin-
guished statistically.Fig. 3. (a) Network and (b) cladogram representing relationships between 11-
locus haplotypes of APOE.We also performed a cladistic analysis using eHap for ε2/ε3/ε4
haplotypes as a simple contrast of haplotypes on the cladogram
ε4–ε3–ε2. When ε4 is contrasted with ε3, while estimating the
effect of ε2 as a nuisance parameter, the contrast is highly signi-
ficant, and thus the nodes remain distinct (χ2 =79.75, df=1,
p∼0). When ε2 is contrasted with ε3, while estimating the effect
of ε4 as a nuisance parameter, the contrast is not quite significant,
and thus the nodes collapse for purposes of estimation
(χ2 =3.48, df=1, p=0.062). The latter result is typical for
samples of this size; the small protective effect of ε2 is evident in
the odds, but it is not significant. The odds of AD for the
combined set of ε2 and ε3 haplotypes is roughly fivefold less than
that for ε4.
SNPs inside/outside of APOE
Using MHAwe found a cluster of high-risk haplotypes, all of
which contain ε4 alleles, and another cluster of low-risk
haplotypes that contain either ε2 or ε3 alleles. Thus, for these
data and MHA, we find no evidence that SNPs elsewhere in
APOE, such as in its regulatory region, have a significant impact
on risk for AD. We would have reached the same conclusions
fitting AD status to two SNP models in which one SNP is always
represented by the ε4 allele count as we show now.
We imagine two scenarios, one in which one analyzes
association with AD status without knowledge of ε4 status and
one in which one appropriately conditions on ε4 count. Forty
SNPs were informative enough in the AD and control samples
to produce valid tests (see Supplementary Table 1). It is
apparent that, in the absence of information about ε4 count,
many loci in the region show significant association with AD
status even after Bonferroni correction (Fig. 4). In fact, of the 40
informative loci, 28 SNPs have p≤0.05 and 12 are less than the
Bonferroni cutoff of 0.00125. Multiple SNPs in TOMM40 and
APOE, and at least one SNP in LU, PVRL2, APOC1, APOC4,
and CLPTM1, were associated with AD risk. In our sample, the
association with AD was significant (p<0.05) for APOE SNPs
−491 (SNP 21) and +113 (SNP 25), but not for −427 (SNP 23),
Table 3
Number of AD and control subjects by TOMM40 SNP 10 and APOE ε4
genotypes
TOMM40, SNP 10 APOE
Cases Controls
CC CT or TT CC CT or TT
CC 24 8 1 9
CT or TT 5 144 0 217
661C.-E. Yu et al. / Genomics 89 (2007) 655–665−219 (SNP 24), or +5361 (SNP 37). However, when ε4 count is
incorporated into the model and after Bonferroni correction, no
locus has a significant, independent effect on AD status (Fig. 4).
MHA for logical units across this region, such as genes,
produces the same conclusion (data not shown). In general,
when MHA is performed without conditioning on ε4 count,
certain portions of the cladogram do not “collapse” into a single
node, suggesting some haplotypes were different in their impact
on AD risk. However, when ε4 count is introduced as a
covariate, the cladograms always collapsed into a single node,
which is consistent with the null hypothesis that haplotypes
have no impact on risk for AD.
TOMM40 SNP 10 versus APOE ε4
Of these results, the association of SNPs in TOMM40 with
AD, especially SNP 10 (rs157581), is arguably most intriguing.
The C allele of SNP 10 in TOMM40 is in very strong LD with
the C allele of SNP 33 in APOE, which defines the ε4 allele. The
correspondence is so strong (Table 3) that one might wonder
how the statistical models favor ε4 as the risk allele. But there is
information to distinguish the effects. For an additive (allele)
logit model, the odds ratio for the presence of ε4 versus the
status of AD is estimated to be 4.1, whereas the odds ratio for
AD status using the alleles of SNP 10 is 2.88. Moreover, when
variables representing both SNPs are entered into the logit
model, either with or without an additional interaction term
between the two SNPs, only the effect of APOE ε4 count is
significant.
Perhaps the effects of the TOMM40 SNP 10 alleles are not
additive, but they are expressed recessively. Consider indivi-
duals who are doubly homozygous for C alleles (at TOMM40
and APOE), homozygous for C alleles only at SNP 35 of
APOE, homozygous for C alleles only at SNP 10 of TOMM40,
or homozygous for neither. The case/control counts for these
multilocus genotype classes are 24/1, 5/0, 8/9, and 144/217.
From the contrast of 5/0 to 8/9, it appears that risk solely or
predominantly arises from ε4 homozygotes, because the SNP 10
CC homozygotes are about equally likely to occur in case and
control individuals who are not homozygous for ε4.
Discussion
The ε2/ε3/ε4 system of alleles in APOE appears to play a
crucial role in risk for LOAD. In fact, as much as 50% of the
population risk for LOAD could be attributable to ε4 alone [4].
For the past decade, however, other loci in APOE and sur-
rounding genes have also been associated with risk for LOAD.For instance, variation in the 5′ region of APOE has been shown
to alter the expression of the gene, to produce population-level
variation in metabolic lipid levels [3], and to have a weak
impact on risk for LOAD [9]. Among the APOE promoter
SNPs, the −491 A, −427 C, and −219 T variants have a higher
frequency in AD cases than in controls in some, but not all,
studies [25–30]. Nonetheless, the impact of other loci has
proven difficult to define because of their known or potential
LD with SNP 33, which defines the ε3/ε4 dichotomy.
Surprisingly, only a few studies have undertaken a comprehen-
sive assessment of the patterns of LD in the APOE region [31],
and none of those studies have used molecular methods to
ensure the accuracy of phased chromosomes. We provide a
comprehensive assessment of LD by using molecular haplotyp-
ing to phase 21 SNPs in APOE itself [18] and complementary
statistical methods for an additional 29 SNPs surrounding
APOE.
In our Caucasian sample, the association with AD was sig-
nificant for APOE promoter SNPs −491 (SNP 21) and +113
(SNP 25). However, when ε4 count is incorporated into the
model and after Bonferroni correction, no locus has a significant,
independent effect on AD status. As for SNPs outside of APOE,
one locus in our comprehensive analysis, a synonymous SNP in
the TOMM40 gene, accounts for increased risk for developing
AD. Again, when ε4 status is accounted for in the model, no
single SNP explains a significant portion of the risk. Therefore,
while tight LD between APOE and TOMM40 raises the
possibility that the latter locus may contribute to the risk for
developing AD, ε4 remains the most likely LOAD allele in the
region.
Within APOE itself, we genotyped 21 previously reported
SNPs, but found only 16 to be polymorphic in our samples of
550 individuals, of which 11 had MAF >0.02. These 11 SNPs
cover 4802 bp of genomic sequence. Thus, within APOE, an
SNP with MAF >0.02 occurs every 437 bp, on average. This
density of SNPs is slightly higher than what is observed, on
average, from completely sequenced genes in general [32]. For
the ε2/ε3/ε4 system of alleles, we found that ε4 is embedded in
12 different haplotype backgrounds; ε3 is embedded in 20
different haplotype backgrounds; while ε2 is embedded in only
3 backgrounds (Table 1). Because there were 298 haplotypes
bearing ε4 and 741 bearing ε3, there is proportionately more
variety in ε4-bearing haplotypes than in ε3-bearing haplotypes
(on average, 24.8 copies per ε4 haplotype versus 37.1 copies per
ε3 haplotype). This observation is consistent with the conjecture
that ε4 is ancestral to ε3, based on analyses of other primates
[33], all of which carry the ε4 allele. Nonetheless, the fact that ε3
is now far more common in human populations worldwide has
led to the conjecture that ε3 has been under positive selection
since its introduction in early humans [19]. Consistent with our
observation that variation in APOE is at least as large as that
seen in other genes, however, Fullerton et al. [19] could find no
statistical evidence for selection, which would be expected to
reduce regional variation.
If “haplotype block” structure is measured by the distribution
of haplotypes, our analyses suggest most of the SNPs in APOE
exist in a single block. In fact, only five haplotypes account for
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if LD is measured pair-wise by r2 (Supplementary Fig. 1), or
even by multivariate assessment of LD based on pair-wise r2
(Supplementary Fig. 2), our analyses suggest much less LD.
This result suggests that this contrast underscores the super-
iority of assessing multivariate LD, such as by analysis of the
distribution of haplotypes.
To make the drawback of pair-wise LD more concrete, we
offer a simple example. Imagine that there exists (or historically
existed) a population in which there are five linked SNPs, with
alleles named “1” and “2”. Alleles at the loci are independent
and thus all 32 possible haplotypes occur. From this population
a sample is drawn to found a new population. The sample
contains only 4 haplotypes (Table 4), each of which occurs with
probability 0.25. As can be seen in Table 4, while the haplotype
distribution is limited, the founder haplotypes set up a peculiar
pattern of pair-wise LD, regardless of the measure of LD used
(see Devlin and Risch [21] for discussion). Pairs of adjacent loci
are pair-wise independent, while more distant pairs of loci are
either in absolute LD or independent. While artificial, this
scenario makes two points: pair-wise LD can fail to capture
higher level LD, even in very simple instances (known in
statistics as Simpson’s paradox) and comparisons of pair-wise
LD across and within genomic regions potentially confound an
evolutionary parameter of interest, namely the recombination
rate, with founder effect. This confounding will be most
important for recently founded populations, but we suspect it is
also important for other populations, such as those of European
and Asian decent.
Our experimental design oversamples for individuals diag-
nosed with LOAD. Devlin and Risch [21] and Devlin et al. [34]
have shown that various measures of pair-wise LD can be biased
in the face of this oversampling. Due to this bias, one might
expect the patterns of LD to differ substantially between the
LOAD and the control samples. Instead we see similar patternsTable 4
Heuristic example of the failure of pair-wise LD to capture higher level LD
Haplotype Loci
a b c d e
1 1 1 1 1 1
2 1 2 1 2 1
3 2 1 2 1 2
4 2 2 2 2 2
Loci Disequilibrium
a b c d e
a 0 1 0 1
b 0 0 1 0
c 1 0 0 1
d 0 1 0 0
e 1 0 1
The four haplotypes occur with equal probability, 0.25, in the population. Pair-
wise LD, as measured by r2 (but true also of any measure of LD reviewed by
Devlin and Risch [21]), fluctuates in a peculiar pattern and fails to capture the
higher level features of LD, namely that only 4 of the possible 32 haplotypes
occur in the population.for both samples (Fig. 2, Supplementary Figs. 1 and 2), although
the controls show somewhat stronger LD. These patterns are
probably due to the fact that SNPs 33 and 35, defining the ε2/ε3/
ε4 system, are not in high LD with many other genotyped SNPs
in the region. If they were tightly linked, we would expect more
divergent patterns in the two samples.
As described in more detail by North et al. [31], the pattern of
LD in the region has implications for the power to detect the
association between ε2/ε3/ε4 and LOAD, assuming that this
system of alleles was not genotyped but other SNPs in the
region were. Two cross-currents complicate predictions about
detection. As seen in Fig. 2, LD as measured by r2 is not large,
yet this is the natural measure for power due to its direct
connection to the χ2 statistic [35]. On the other hand, the
strength of the association between LOAD and the ε2/ε3/ε4
system is substantial. Assuming an odds ratio for ε4 versus ε3 in
the LOAD versus control samples of about 2.0 and assuming
that the frequency of ε4 in the population is 0.12, to detect the
association with ε4 with 80% power at a significance level of
0.05 would require roughly 100 individuals diagnosed with
LOAD and an equal number of controls. To detect the ε4
association by genotyping a locus in LD would require samples
of size of roughly N/r2 [35]. Even if r2 were as small as 0.1, the
required sample size for 80% power under these assumptions is
only about 1000 cases and controls.
Scanning the region within and around APOE, there is only
one set of SNPs that show large LD, as measured by r2, with the
ε2/ε3/ε4 system of alleles (Fig. 2, Supplementary Figs. 1 and 2).
These loci fall in TOMM40, roughly 15 kb 5′ of APOE. SNPs
within this region (SNPs 8–12, Fig. 1) have some of the
strongest genetic associations with the risk for AD in our
Caucasians AD samples (Supplementary Table 1). TOMM40
encodes a subunit of the multisubunit translocase of the outer
mitochondrial membrane, the TOM complex [36], which plays
a role in protein transport into mitochondria. In fact, the TOM40
protein forms the critical pore and actively sorts protein for
submitochondrial locations [37]. Because structural abnormal-
ities and oxidative stress of the mitochondria are known to
increase risk for AD and because defects in mitochondrial
energy metabolism have been observed in AD [38–41], the
possibility exists that part of the liability for LOAD commonly
ascribed to ε4 might be caused by TOMM40 on the basis of its
strong LD. However, contrasting the effects of all 50 loci in this
region on the risk of AD, with and without conditioning on ε4
status, our findings diminish the possibility that TOMM40 or
other loci near APOE may have a major effect on the risk of
LOAD in Caucasians.
Our results support the idea that associations can be detected
at SNPs near a complex disease gene when the causative
mutations are essentially monophyletic, as for APOE ε4.
However, a high density of SNPs will be necessary to ensure
the detection of such association with causative disease
changes. Our study provides an excellent scenario to support
this point of view. Because TOMM40 has functional implica-
tions in AD pathogenesis and it shows strong genetic
association with LOAD, if the APOE ε4-defining SNP (SNP
33 [rs429358]) was not genotyped and analyzed in the study,
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gene for LOAD. Thus, enormous research effort could be in
vain by studying the incorrect genes. Moreover, our study
further demonstrates that haplotype-based analysis can provide
additional information with respect to tests of significance and
fine localization of the most critical causative variants.
Materials and methods
Study samples
Human subjects were collected by the University of Washington
Alzheimer’s Disease Research Center. All were unrelated individuals of
European ancestry. The samples consisted of 193 individuals diagnosed with
LOAD, 232 similarly aged subjects with no cognitive impairment, and 125
individuals with various other neurodegenerative disorders, including possible
LOAD, dementia with Lewy bodies, Parkinson disease, progressive supra-
nuclear palsy, and frontotemporal dementia.
SNPs genotyped
Fifty potentially variable sites were genotyped in this study, as mapped in
Fig. 1. Twenty-one of these SNPs fall in APOE and its potential 5′ regulatory
region, which covers roughly 5300 bp of genomic sequence, and were
genotyped by primer extension assays using the SNuPE assay reagents [18].
SNPs within APOE were selected according to the study of Fullerton et al. [19]
and described in detail previously [18]. An additional 29 SNPs were chosen to
evaluate other genes/genomic elements that were proximate to APOE and could
plausibly affect risk for LOAD. Sixteen fall within roughly 114 kb 5′ of APOE;
the remaining 13 fall within roughly 82 kb 3′ of APOE (Fig. 1, Supplementary
Table 1). These proximate SNPs were genotyped by TaqMan allele discrimina-
tion assays (Applied Biosystems, CA, USA).
Genotyping error
By our computational analysis, we wished to estimate the probability that a
single error introduced into a naturally occurring haplotype—defined as a
haplotype that occurs at least twice in the sample—would produce a pseudo-
haplotype instead of a naturally occurring haplotype. To estimate this probability
pSH we iteratively performed the following experiment: (1) randomly draw a
haplotype from the distribution of naturally occurring haplotypes, (2) randomly
select one of the L=11 polymorphic loci, (3) change the selected base pair to its
complement, and (4) determine whether the resultant haplotype was also in the
naturally occurring haplotype list. Performing this experiment a million times
yielded the estimated probability of producing a pseudo-haplotype by error,
which was pSH=0.792. If this experiment were performed using all variable
loci, L=16, it would yield a slightly higher probability estimate; if more than
one locus were altered on a haplotype, the estimated probability would be
substantially larger.
To determine if any of the singleton haplotypes were pseudo-haplotypes, we
started with the genomic DNA from the 12 samples containing singleton
haplotypes. These samples were scored by direct sequencing instead of primer
extension reactions, which allowed us to generate completely independent
results from the previous experiments. Among the 12 samples, 9 were consistent
with the previous results. Three subjects, however, showed inconsistency at a
single SNP. Two of these errors were clerical, occurring when the data were
entered by hand; the other error was due to a rare SNP that disrupted one of the
priming sites for primer extension reaction. Thus from our data we would
estimate the probability of drawing a singleton haplotype with a single error,
pE,S, to be 3/1100≈0.00272, with 6 of 12 singleton chromosomes representing
an upper 96% confidence interval on the number of errors, given binomial
sampling, to give a 96% upper confidence interval of ≈0.00544. Two of these
errors occurred for SNPs with MAF >0.02.
If we assume that errors are independent across loci on a haplotype and
across haplotypes, it is straightforward to develop an estimator for the pro-
bability ε of an error on an individual SNP, namely ε≈pE,S/(L×pSH). TakingL=11, and plugging in our estimates obtained from the molecular and
computational analyses, we estimate a per-locus error rate of 0.00031. Two
observations also follow from these calculations: the probability of haplotypes,
natural or pseudo, with two or more errors on them is negligible, and roughly
four other haplotypes are expected to be erroneous, but they mimic naturally
occurring haplotypes and cannot be corrected.
Molecular haplotyping methods
To produce molecular haplotypes for 21 loci in APOE from our study
samples, we used the ADLAPH method described in Yu et al. [18]. Briefly,
ADLAPH combines allele-discriminating primers and long-range PCR
amplification to amplify long genomic fragments from only one of the two
chromosome homologues of a particular subject. The phase-separated long-
range PCR product is then genotyped by standard methods to yield one
haplotype. Contrast with the original diploid genotypes is then carried out to
provide the complementary haplotype. Comparisons between molecular and
computational haplotyping methods have been previously discussed in our
other studies [18,42]. For a small region with tight LD (such as the entire
APOE gene), the computational methods do not differ substantially in their
estimates of haplotype distributions [18]. However, when a larger region
without tight LD was analyzed, the molecular haplotypes increased the
linkage information by as much as 9% over the unphased SNPs [42]. In this
example, marker phase resolution via molecular haplotyping led to modest
increases in the evidence for linkage in these data. Yet, larger gains may be
possible in datasets with greater inherent phase ambiguity, such as in studies
with larger numbers of markers, more polymorphic markers, or weaker LD
between markers.
Statistical methods
Haplotype frequencies comprising SNPs outside of APOE were inferred by
using maximum likelihood as implemented in the eHap program [43] (see
CompGen Web site: http://wpicr.wpic.pitt.edu/WPICCompGen/). To account
for the phase-known haplotypes of APOE, we recoded haplotypes as alleles
and the eHap program was specifically tailored to account for absolute
haplotypes. Single SNP and haplotype-based statistical analyses were per-
formed using the eHap program [43]. eHap relates haplotypes to phenotypes by
using likelihood techniques that account for haplotype uncertainty. The
program offers a flexible set of hypothesis tests, including goodness-of-fit or
omnibus tests and specified contrasts of association between haplotypes and
phenotypes.
To estimate haplotypes at all 50 loci and to infer regions of greater than
expected frequency of recombination (recombination hot spots), we used Phase
(Version 2.0) [44–46]. Phase uses Bayesian methods for inference, based on the
assumption that the evolutionary relationships among haplotypes can be
imputed from their degrees of similarity. LD block structure was defined in the
sense of Rinaldo et al. [20], namely blocks are regions of limited haplotype
diversity. To identify blocks, we used Entropy Blocker (CompGen). Using
output from Phase, its algorithm identifies those regions that exhibit substantial
multilocus disequilibrium, ranging over a substantial number of SNPs, while
allowing one or more SNPs to separate blocked regions or adjacent blocks. The
model computes the likelihood of the data minus a penalty for model
complexity, using the criteria that blocks should have very low haplotype
diversity and that the LD with SNPs outside a block should be small. Entropy
Blocker was also used to visualize pair-wise LD.
To select “tagging SNPs,” we used H-clust [20] (CompGen). The
algorithm in H-clust identifies highly correlated sets of SNPs and chooses an
SNP within each correlated cluster to represent the cluster. Input data are
multilocus genotypes, which are transformed into a per-locus count of the
minor alleles (0, 1, or 2). This transformed matrix of multilocus genotypes is
then itself transformed into a correlation matrix from which clusters of SNPs
are identified by hierarchical clustering. Within each cluster, the SNP that is
most highly correlated with other SNPs in the cluster is chosen as its tag
SNP.
We use MHA [24] to evaluate haplotype associations with AD. MHA uses
inferred evolutionary relationships among haplotypes, specified in the form of a
cladogram (an unrooted evolutionary tree), to structure the tests of association.
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[43]. To perform this cladistic analysis, the cladogram is divided into subgroups
(clades): individual haplotypes occurring as leaves (terminal nodes) on the tree
represent 0-step clades; 1-step clades are produced by moving backward one
mutational step from the 0-step clades toward internal nodes and then this
procedure is repeated to produce the 2-step clades and so forth. For inference, a
series of 1-degree-of-freedom tests is performed in a sequential fashion based on
the clades, from 0-step clades onward. At each step in the algorithm, a full model
is fit. The full model is the same within each step, but changes between steps,
conditional upon the results of the previous step, with the goal of testing whether
clades differ in their impact on phenotype, in this case risk of AD. MHA has
been used in a variety of settings [47–50].
Results for MHA are reported in detail only for the molecularly haplotyped
SNPs in APOE. For SNPs outside of APOE, we performed MHA for SNPs
occurring in logical clusters, such as genes, and we fit additive logit models
based on the count of alleles at the locus of interest; for both kinds of analyses,
we “conditioned” on ε4 genotype by entering the count of ε4 alleles as a co-
variate in the models.
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